Is MetaVia Inc. (MTVA) a Buy, Sell, or Hold?
NASDAQ : MTVA
MetaVia Inc.
$1.48 USD
-$0.03 (-1.99%)
- Volume
- 68.03K
- Average Volume
- 3.97M
- Market Capitalization
- $3.26M
- P/E Ratio
- -0.25
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $19.03
- Year Low
- $0.97
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.73
Company Overview
NASDAQ
Hyung Heon Kim
Biotechnology
Healthcare
MTVA
8
US
USD
Liquidity Metrics
0.02
2.73
2.73
2.64
0.00
Sales & Valuation
-$
0.00
0.79
-0.22
-3.12
Profitability
-$7.35
-$12.97M
0.00%
0.00%
-172.92%
-91.22%
P/E Metrics
-0.25
0.00
0.00
Analyst Price Target & Rating
3/5
2 Analysts
%
Financial Health Scores
-16.72
1/9
$8.97M
$14.39M
$5.32M
-$13.12M
Key Metrics (TTM)
-$10.28M
0.00
0.78
2.73
-172.92%
-149.42%
-182.49%
-464.87%
-24504 days
Company Executives
| Name | Title |
|---|---|
| Hyung-Heon Kim | Chief Executive Officer, President & Director |
| Marshall H. Woodworth | Chief Financial Officer |
| Michael C. Pine | Senior Vice President of Business Development Advisor |
| W. Christopher Fang | Consulting Chief Medical Officer & Advisor |
| Robert Homolka | Senior Vice President of Clinical Operations |
| Mi-Kyung Kim | Chief Scientific Officer |
Poll Results
No votes yet today — be the first to share your view!
About MetaVia Inc. (NASDAQ:MTVA) Stock
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development spe ... cifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
2026-07-09 08:31:00
All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg Topline Data Remains on Track for Fourth Quarter 2026 CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts.
2026-06-17 08:31:00
CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Wednesday, June 24, 2026 at 10:30 am ET.
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
2026-06-09 07:00:00
POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the appointment of Mark Glickman, Steven D.
2026-06-08 08:31:00
DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Vanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Weight-Loss Effects in Preclinical MASH Model Vanoglipel Combined with Metformin Demonstrated Enhanced Glycemic Control and Body Weight Reduction Versus Monotherapy in a Preclinical T2D Model CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Association's (ADA) 2026 Scientific Sessions, held June 5–8 in New Orleans, Louisiana.
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
2026-06-04 08:31:00
CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H.
2026-05-27 08:31:00
48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose Levels CAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin (OXM) analog agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), in a late-breaking poster presentation at the European Association for the Study of the Liver Congress 2026 (EASL 2026), being held May 27–30 in Barcelona, Spain.
Why MetaVia Stock Is Surging On Friday?
2026-05-22 12:03:03
Discover why MetaVia Inc. (NASDAQ: MTVA) stock is surging on Friday following new peer-reviewed data on its MASH treatment, reversing Thursday's dip.
Why MetaVia Stock Is Falling On Thursday?
2026-05-21 14:30:26
MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing peer-reviewed data supporting its anti-fibrotic MASH drug candidate.
Frequently Asked Questions
-
What is the current MetaVia Inc. (MTVA) stock price?
-
MetaVia Inc.(NASDAQ:MTVA) stock price is $1.48 in the last trading session. During the trading session, MTVA stock reached the peak price of $19.03 while $0.966 was the lowest point it dropped to. The percentage change in MTVA stock occurred in the recent session was --1.99% while the dollar amount for the price change in MTVA stock was -$0.03.
-
MTVA's industry and sector of operation?
-
The NASDAQ listed MTVA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MTVA?
-
Hyung-Heon Kim | Chief Executive Officer, President & Director
Marshall H. Woodworth | Chief Financial Officer
Michael C. Pine | Senior Vice President of Business Development Advisor
W. Christopher Fang | Consulting Chief Medical Officer & Advisor
Robert Homolka | Senior Vice President of Clinical Operations -
How many employees does MTVA have?
-
Number of MTVA employees currently stands at 8. MTVA operates from 545 Concord Avenue, Cambridge, MA 02138, US.
-
Link for MTVA official website?
-
Official Website of MTVA is: https://www.metaviatx.com
-
How do I contact MTVA?
-
MTVA could be contacted at phone #857 702 9600 and can also be accessed through its website. MTVA operates from 545 Concord Avenue, Cambridge, MA 02138, US.
-
How many shares of MTVA are traded daily?
-
The average number of MTVA shares traded daily for last 3 months was 3.97M.
-
What is the market cap of MTVA currently?
-
The market value of MTVA currently stands at $3.26M with its latest stock price at $1.48